Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

about

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.Temporal and geographic variation in the systemic treatment of advanced prostate cancer.

P2860

Q51244133-C846EE44-7A5D-402E-89F2-08996D0F1EB1 Q53704242-90DB8DF4-A992-4262-81E6-5A175D01734A

P2860

Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

Item

http://www.wikidata.org/entity/Q38719277

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Early National Dissemination o ...... ate Cancer in Medicare Part D.

@en

type

Item

label

Early National Dissemination o ...... ate Cancer in Medicare Part D.

@en

prefLabel

Early National Dissemination o ...... ate Cancer in Medicare Part D.

@en

P1476

Early National Dissemination o ...... ate Cancer in Medicare Part D.

@en

P2093

Bhramar Mukherjee

http://www.w3.org/2001/XMLSchema#string

Brent K Hollenbeck

http://www.w3.org/2001/XMLSchema#string

David C Miller

http://www.w3.org/2001/XMLSchema#string

Hye-Sung Min

http://www.w3.org/2001/XMLSchema#string

Jennifer J Griggs

http://www.w3.org/2001/XMLSchema#string

Megan E V Caram

http://www.w3.org/2001/XMLSchema#string

Ted A Skolarus

http://www.w3.org/2001/XMLSchema#string

Tudor Borza

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Factors affecting the uptake of new medicines: a systematic literature review

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Why don't physicians follow clinical practice guidelines? A framework for improvement

Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.

Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.

Variations in physician practice: the role of uncertainty.

Understanding of regional variation in the use of surgery.

P304

e694-e702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2016.020206

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28628393

http://www.w3.org/2001/XMLSchema#string

P932

5555032

http://www.w3.org/2001/XMLSchema#string

Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

about

P2860

P2860

Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932